Home / Psoriasis (page 10)


Here you will find the latest clinical research on psoriasis.

Effect of Secukinumab in the Treatment of Psoriatic Arthritis (SATURN)

  Purpose The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the …

Read More »

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

  Purpose The main purpose of the current study will be to provide real – world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis. Condition Psoriasis Study Type: Observational [Patient Registry] Study Design: Observational Model: CohortTime Perspective: Prospective …

Read More »

Initial Treatment With Golimumab in Early PsA

  Purpose The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA). Afterwards, a 28 week open label phase with methotrexate alone is started. Golimumab will be discontinued. Hypotheses: First, the investigators hypothesize that initiation …

Read More »

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium (OTELO)

  Purpose OTELO is a national (Belgium), multicentre, prospective, non-interventional, post-marketing study. The study will include a representative sample of approximately 250 patients with moderate-to-severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label and reimbursement criteria. Patients may be …

Read More »

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

  Purpose The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches). Condition Intervention Phase Psoriasis Drug: CNTO …

Read More »

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1)

  Purpose The purpose of this study is to compare the safety and efficacy of secukinumab monotherapy and adalimumab monotherapy in patients with active psoriatic arthritis who are naïve to biologic therapy and are intolerant or having inadequate response to conventional DMARDs Condition Intervention Phase Psoriatic Arthritis Biological: Secukinumab Biological: …

Read More »

Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis

  Purpose This study is to evaluate the efficacy and safety of topical application of NP000888 ointment compared to vehicle in plaque and fingernail psoriasis subjects. Duration of administration: 24 weeks Condition Intervention Phase Psoriasis Drug: NP000888 Drug: Vehicle Phase 2 Study Type: Interventional Study Design: Allocation: RandomizedIntervention Model: Parallel …

Read More »

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab (RAPSODI)

  Purpose The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea. Condition Psoriasis Study Type: Observational Study Design: Observational Model: CohortTime Perspective: Prospective Official Title: Real-World Outcome of Psoriasis Patients in Korea on Adalimumab …

Read More »

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis (CALYPSO)

  Purpose CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with moderate to severe plaque psoriasis. Condition Intervention Phase Psoriasis Biological: BCD-057 Biological: Humira® …

Read More »